Should I Buy PEN? PEN 2026 Analysis

Should You Buy Penumbra Inc (PEN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

359.030

1 Day change

-0.10%

52 Week Range

362.410

Analysis Updated At

2026/01/26

Penumbra Inc. is not a strong buy at the moment for a beginner, long-term investor. While the company has shown strong financial performance and positive growth trends, the pending acquisition by Boston Scientific creates uncertainty regarding its future stock performance. Additionally, the stock is currently overbought based on RSI, and analysts have downgraded their ratings due to the acquisition. It is better to hold off on buying until there is more clarity on the acquisition's impact or a more favorable entry point.

Technical Analysis

The stock is in a bullish trend with moving averages indicating upward momentum (SMA_5 > SMA_20 > SMA_200). However, the RSI_6 at 80.218 indicates the stock is overbought, suggesting limited immediate upside. The MACD is positive but contracting, showing weakening momentum. Key resistance levels are at 358.08 and 375.169, with support levels at 330.42 and 302.759.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Strong financial performance in Q3 2025, with revenue up 17.82% YoY and net income up 55.28% YoY.
Positive sector outlook for MedTech in 2026, with strong demand and innovation driving growth.
Analysts highlight potential catalysts like Thunderbolt approval and data readouts.

Neutral/Negative Catalysts

Pending acquisition by Boston Scientific creates uncertainty and has led to analyst downgrades.
Concerns over high purchase multiples affecting returns from the acquisition.
Investigation into potential fiduciary duty breaches related to the acquisition.

Financial Performance

In Q3 2025, Penumbra reported strong financial growth: Revenue increased by 17.82% YoY to $354.7M, net income increased by 55.28% YoY to $45.85M, and EPS rose by 56% YoY to 1.17. Gross margin improved to 67.78%, up 1.86% YoY.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst sentiment is mixed. While some firms like JPMorgan and Citi have upgraded the stock recently due to positive catalysts and sector rotation, others like Truist and Baird have downgraded it to Neutral or Hold due to the pending acquisition. The price targets range from $340 to $374, with most analysts citing uncertainty from the acquisition as a reason for caution.

15 Analyst Rating

Wall Street analysts forecast PEN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PEN is 344.64 USD with a low forecast of 266 USD and a high forecast of 388 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

14 Buy

1 Hold

0 Sell

Strong Buy

Current: 359.400

Low

266

Averages

344.64

High

388

Current: 359.400

Low

266

Averages

344.64

High

388

Truist

Buy

Hold

downgrade

$370 -> $374

AI Analysis

2026-01-16

Reason

Truist

Price Target

$370 -> $374

AI Analysis

2026-01-16

downgrade

Buy

Hold

Reason

Truist downgraded Penumbra to Hold from Buy with a price target of $374, up from $370. The firm cites the recent announcement of its acquisition by Boston Scientific for the downgrade. The deal is highly likely to close without issue, the analyst tells investors in a research note.

Baird

David Rescott

Outperform -> Neutral

downgrade

$345 -> $374

2026-01-16

Reason

Baird

David Rescott

Price Target

$345 -> $374

2026-01-16

downgrade

Outperform -> Neutral

Reason

Baird analyst David Rescott downgraded Penumbra to Neutral from Outperform with a price target of $374, up from $345. The firm cites the pending acquisition by Boston Scientific for the downgrade.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PEN

Unlock Now

PEN Should I Buy

PEN Should I Buy

Should You Buy Penumbra Inc (PEN) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch